Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $20.83.

A number of brokerages recently weighed in on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday. William Blair started coverage on Altimmune in a research note on Friday, February 28th. They set a “market perform” rating for the company. Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. Finally, UBS Group started coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $5.96 on Wednesday. The company has a market capitalization of $423.91 million, a price-to-earnings ratio of -3.85 and a beta of 0.19. The firm’s 50 day simple moving average is $6.78 and its 200 day simple moving average is $7.19. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $11.77.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Equities research analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently made changes to their positions in ALT. Creative Planning grew its stake in shares of Altimmune by 20.5% during the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after acquiring an additional 3,132 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Altimmune by 119.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock worth $250,000 after acquiring an additional 22,188 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Altimmune during the 3rd quarter worth approximately $207,000. Charles Schwab Investment Management Inc. grew its stake in shares of Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC bought a new position in shares of Altimmune during the 3rd quarter worth approximately $31,000. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.